20cm速递｜科创创新药ETF国泰（589720）涨超1.1%，医保数据开放或加速行业创新

Group 1 - The launch of the National Smart Medical Insurance Competition will enhance the efficiency of innovative drug research and development, with open medical insurance data aiding companies in accurately identifying clinical needs, shortening R&D cycles, and reducing costs [1] - The competition promotes cross-industry collaboration among pharmaceutical companies, technology firms, and research institutions, facilitating resource integration and innovation synergy, thereby accelerating the transition of innovative drugs from the laboratory to clinical application [1] - In the long term, the innovative drug sector possesses high growth potential, with the deepening application of medical insurance data expected to improve both the quantity and quality of innovative drugs, which can capture significant market share and pricing power post-approval [1] Group 2 - The reactivation of the dual financing channels of the Sci-Tech Innovation Board and Hong Kong's 18A model enhances the full-cycle financing capabilities of pharmaceutical companies, while new regulations on traditional Chinese medicine pieces will accelerate industry consolidation, benefiting leading firms and distribution channels [1] - The 11th batch of centralized procurement highlights policy determination, further emphasizing the investment value of innovative drugs [1] - The Guotai Sci-Tech Innovative Drug ETF (589720) tracks the Sci-Tech Innovative Drug Index (950161), which can experience daily fluctuations of up to 20%, focusing on representative companies in the new drug development sector, primarily in biomedicine and chemical pharmaceuticals [1]